Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Cowen & Co. Downgrades PhaseBio Pharmaceuticals to Market Perform

Cowen & Co. analyst Phil Nadeau downgrades PhaseBio Pharmaceuticals (NASDAQ:PHAS) from Outperform to Market Perform.
byBenzinga Newsdesk
October 24, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Cowen & Co. analyst Phil Nadeau downgrades PhaseBio Pharmaceuticals (NASDAQ:PHAS) from Outperform to Market Perform.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

What’s Going On With Beamr Imaging Stock?

By Erica Kollmann
April 9, 3:28 PM
Beamr Imaging shares are trading higher Tuesday after the company announced it will demonstrate a real-time video optimization application with Nvidia's Holoscan for Media. "Livestreams are being revolutionized by emerging workflows that demand greater efficiency and flexibility," said Sepi Motamedi, Senior Product Marketing Manager for Live Media Solutions at NVIDIA.

BMR

Read More

LivePerson Bounces Following Post-Earnings Massacre: A Look At The AI Software Stock

By Melanie Schaffer
March 17, 12:19 PM
LivePerson Inc (NASDAQ: LPSN) was bouncing up about 6% on Friday after a big bearish day on Thursday caused the stock to plunge a whopping 60%. The massive decline was in reaction to LIvePerson’s earnings results, which were released after the market closed on Wednesday.

LPSN